Angiosarcoma clinical trials at UCSF

2 in progress, 1 open to eligible people

Angiosarcoma is a rare cancer that affects blood vessel linings. UCSF is conducting trials to explore new personalized treatments for breast cancer. These trials focus on matching new drugs with patient-specific needs.

Showing trials for

  • I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    open to eligible people ages 18 years and up

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.

    San Francisco, California and other locations

  • Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

    Sorry, not yet accepting patients

    This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.

    San Francisco, California

Our lead scientists for Angiosarcoma research studies include .

Last updated: